Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. - Wikidata - wikimedia - TriplyDB

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

http://www.wikidata.org/entity/Q36857368

about

Management of Pemphigus Vulgaris Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Shifting Focus in the Therapeutics of Immunobullous Disease.Rituximab: A Magic Bullet for Pemphigus Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.Rituximab therapy improves recalcitrant Pemphigus vulgaris.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Setting the target for pemphigus vulgaris therapy.Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris.Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.Pemphigus vulgaris: an evidence-based treatment update.The emerging role of rituximab in autoimmune blistering diseases.Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.Acquired haemophilia treated successfully with rituximab in a patient with pemphigus vulgaris.Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.Rituximab as Single Long-term Maintenance Therapy in Patients With Difficult-to-Treat Pemphigus.Rituximab in pemphigus.Pemphigus Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis

P2860

Q26747092-CC2F4246-0C3D-4B6F-A291-F2CAE54F7212 Q28276800-8EFDEB07-CE9E-4996-8C58-763B6F1A4AA0 Q33737974-032F93E7-405F-423C-A7ED-60DF72BEA137 Q33741941-041E50B1-9417-44E9-AA03-BABD034FA6F8 Q34964558-4B870C7F-0140-4E95-9410-C918458882AA Q36008711-307339DD-62FD-4517-BDE4-444F7ED267AC Q37620483-D6CFE4F7-E5FD-4FBA-A239-CC4DBBA36C5D Q37677416-9F97DA22-5FC0-4AD2-933F-9C84A4DB35DD Q38072118-C133B6D7-A17D-46BD-9DA2-491DD89F8005 Q38077282-6B8B9746-5F4E-4D6C-B8EA-62A1D5482E5D Q38114909-EFC9DABE-4495-4713-86BE-0890D4E05536 Q38154934-0A616144-162C-4ECE-B05B-8A7FC39F808A Q38245848-4A15AE37-435F-4E89-B661-E73E7B98C98A Q38345404-47AD4EB5-D020-4FDB-98DA-A1D67A37A3D8 Q38384497-5FE0AAB8-ABB1-4C8D-A579-CF649CB29158 Q38747187-47B70545-0F9D-4BEB-888B-8ED160D5B2B0 Q39366479-29A08B0C-DAA6-48F8-882A-AF9919AE52BB Q45117048-44049D00-8AA4-416C-98F4-7AE0582B3333 Q45885198-BDBD427C-602E-40CB-92C3-D7CDE5CE9074 Q47837398-3C79BCBC-CFFF-4A37-9695-E28AC4ADD721 Q47977153-0A97F228-B6B0-4AB4-B319-D98719FEE176 Q49332069-B35DC3BA-3354-4FCB-8EF6-46714F9DB86B Q50075561-7429BC29-E83A-4EE8-B8F4-5EE4908855AC Q56603745-F0FA3034-D3C9-45A6-BCDD-4C85C0FFDB76 Q58699318-FE88D25A-A1E5-4ABA-BF3E-FD42F68108C6

P2860

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

http://www.wikidata.org/entity/Q36857368

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

@en

type

label

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

@en

prefLabel

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

@en

P1433

Q36857368-C807F997-40F8-4CD7-9150-E2F27FAAB485

P1476

Q36857368-E7FB461E-6B39-4055-8106-B2E0CF03D6DE

P2093

Q36857368-05F0CC7B-BFCC-4D5F-A883-0EA3B7323E92

Q36857368-12920D3B-3A04-4356-B50C-C13B76DC16F2

Q36857368-4AA8D62B-2F6A-4727-B322-178FF80CAD54

Q36857368-55FF13E2-7B7F-4AD9-9547-57B001B564B6

Q36857368-60B3F1D6-FE53-43F0-8ED4-B3673C9190D6

Q36857368-94EBFCDB-A375-4C5B-8273-07AED80A4DB9

Q36857368-B21B4F51-DB25-46F3-A470-A57972955FDC

Q36857368-D8158AF1-8526-41DB-BBB3-100D406DE02A

P2860

Q36857368-2C8B42ED-20BF-4889-9A07-02CAC4F1C2F8

Q36857368-5EB8ADDE-BC0E-4A54-A323-9751ED7ECC83

Q36857368-6948C500-605E-4ABC-BD17-72234FC1686C

Q36857368-69B47B21-C402-4F4E-A0E4-98F77A021F6C

Q36857368-969B51BC-DBF8-4BA4-862A-61899AA22A3D

Q36857368-BEAB3C65-991B-41B0-9D38-538296DE88AB

Q36857368-D59826A8-BBAD-420B-B8F7-D6F79599E551

Q36857368-E085D03F-4471-4E51-A272-F609C3ACAD80

Q36857368-E0DF5A60-E284-4A05-9006-97DFC115D32B

Q36857368-EEA87ADF-ED69-485B-B4C5-1087DC195F01

P304

Q36857368-2CECF233-1B74-4767-8E78-683F1A1A343B

P31

Q36857368-8A34C603-F8AE-43B0-8EFF-0EA0683DDE63

P356

Q36857368-BB9AD631-7234-4548-AA1A-7DC09144AEB8

P433

Q36857368-4D66D327-EA2B-4F76-9C9F-8C844871A1A3

P478

Q36857368-EF902C9B-D1B8-4694-BD63-D3031C0F0049

P577

Q36857368-30FA3045-6836-4847-AF1D-1AE28F9EB0F8

P698

Q36857368-440E8B37-AB95-45EF-B8CF-BACC5C44FBE6

P932

Q36857368-1B544D59-165A-4F49-8460-FCF1E6684844

P356

ARCHDERMATOL.2012.1522

P1433

JAMA Dermatology

P1476

Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

@en

P2093

Aimee S Payne

http://www.w3.org/2001/XMLSchema#string

Donald E Tsai

http://www.w3.org/2001/XMLSchema#string

John R Stanley

http://www.w3.org/2001/XMLSchema#string

Kathleen J Propert

http://www.w3.org/2001/XMLSchema#string

Kathleen J Tsai

http://www.w3.org/2001/XMLSchema#string

Luisa Lunardon

http://www.w3.org/2001/XMLSchema#string

Nicole Fett

http://www.w3.org/2001/XMLSchema#string

Victoria P Werth

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

A single cycle of rituximab for the treatment of severe pemphigus.

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.

Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.

Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial.

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.

B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses

P304

1031-1036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHDERMATOL.2012.1522

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

148

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22710375

http://www.w3.org/2001/XMLSchema#string

P932

3658473

http://www.w3.org/2001/XMLSchema#string